Imatinib for bleomycin induced pulmonary toxicity: a case report and evidence‐base review

The evidence supporting therapy with imatinib for bleomycin‐induced pneumonitis (BIP) is equivocal. Further experience is needed to establish its role in BIP management. While it may be considered in the management of BIP, it is important to be mindful of the adverse effects including thrombocytopen...

Descripción completa

Detalles Bibliográficos
Autores principales: Banakh, Iouri, Lam, Alice, Tiruvoipati, Ravindranath, Carney, Ian, Botha, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856242/
https://www.ncbi.nlm.nih.gov/pubmed/27190613
http://dx.doi.org/10.1002/ccr3.549
Descripción
Sumario:The evidence supporting therapy with imatinib for bleomycin‐induced pneumonitis (BIP) is equivocal. Further experience is needed to establish its role in BIP management. While it may be considered in the management of BIP, it is important to be mindful of the adverse effects including thrombocytopenia and gastrointestinal bleeding.

Ejemplares similares